Cardurion Pharmaceuticals raised $260 million in a Series B financing led by Ascenta Capital with participation by NEA, GV, and others to advance its innovative medicines for cardiovascular diseases.

Jul 16, 2024•over 1 year ago

Amount Raised

$260 Million

Round Type

series b

BurlingtonScience And EngineeringData And AnalyticsHealth CareBiotechnology

Investors

Bain Capital Private EquityBain Capital Life SciencesDigitalis VenturesDelos CapitalBlue Owl Healthcare OpportunitiesInvusFarallon Capital ManagementMillennium ManagementFidelity Management & Research CompanyGvNeaAscenta Capital

Description

Cardurion Pharmaceuticals, Inc. announced a $260 million Series B financing led by Ascenta Capital, with participation by several new investors and existing ones. The proceeds will be used to support later-stage clinical trials, expand cardiovascular indications for the company’s drug candidates, progress internal discovery programs, and acquire additional therapeutic assets targeting unmet needs in the cardiovascular disease area.

Company Information

Company

Cardurion Pharmaceuticals

Location

78 BLANCHARD ROAD, SUITE 200

Burlington, Massachusetts, United States

About

Cardurion Pharmaceuticals is a next generation cardiovascular company focused on the discovery and development of novel therapeutics for the treatment of heart failure and other cardiovascular diseases. Led by an experienced team of CV experts and industry veterans, we are developing groundbreaking clinical programs in PDE9 and CaMKII inhibition. We take a strategic portfolio approach driven by in-house drug discovery and our office of strategy and have concluded foundational partnerships with key strategics and investors, including an up to $300 million dollar investment from Bain Capital to support current programs and pipeline growth. Cardurion Pharmaceuticals has facilities in Burlington, Massachusetts and Shonan, Japan.

Related People

3 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends